Scarica l'app Stockscreener
11.27
2.59%
-0.30
Pre-mercato:
10.94
-0.33
-2.93%
Precedente Chiudi:
$11.57
Aprire:
$12.06
Volume 24 ore:
20,104
Relative Volume:
0.23
Capitalizzazione di mercato:
$101.07M
Reddito:
-
Utile/perdita netta:
$-40.62M
Rapporto P/E:
-0.5807
EPS:
-19.4076
Flusso di cassa netto:
$-35.63M
1 W Prestazione:
-19.56%
1M Prestazione:
-26.63%
6M Prestazione:
-28.90%
1 anno Prestazione:
+12.98%
Intervallo 1D:
$11.15
$12.06
Intervallo di 1 settimana:
$11.15
$14.22
Portata 52W:
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
11.27 | 101.07M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - kalkine.ca
ProMIS Neurosciences, Inc.(NasdaqCM: PMN) added to S&P Global BMI Index - marketscreener.com
PMN310 shows dose-dependent reduction of amyloid-beta oligomers - scanx.trade
ProMIS Neurosciences at H.C. Wainwright conference: safety stands out By Investing.com - Investing.com Canada
ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com - Investing.com Canada
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Nigeria
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus - Investing.com India
ProMIS Neurosciences (PMN) Edges Up 0.24% to $12.56 as Shares Consolidate Between Support and ResistanceChannel Breakout - siam.in
ProMIS Neurosciences Inc. (PMN) Peer Comparison – Compare with Others - Value Research
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
PMN Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineProfit Inflection Point - dars.gov.et
ProMIS Neurosciences Inc. (PMN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
ProMIS Neurosciences Inc. (PMN) Key Financial Ratios – Valuation, Profitability & More - Value Research
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Revenue Estimate Trend - vinanet.vn
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEarnings Manipulation Risk - vinanet.vn
Q3 EPS Estimates for PMN Raised by Brookline Capital Markets - MarketBeat
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Momentum Breakout Ideas - vinanet.vn
Roth Capital initiates coverage on ProMIS Neurosciences with Buy rating - scanx.trade
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
ProMIS Neurosciences (PMN): Great Point group reports 7.66% beneficial stake - Stock Titan
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... By GuruFocus - Investing.com Canada
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
ProMIS Neurosciences (PMN) Climbs 2.00% to $14.79, Approaching Key Resistance at $15.53Turnaround Stocks - vinanet.vn
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences (PMN) gets 7.77% stake disclosure by Wellington fund - Stock Titan
ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary - TradingView
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights - The Manila Times
ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D - Stock Titan
ProMIS Neurosciences (PMN): Wellington group discloses 7.77% ownership stake - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProMIS Neurosciences Inc expected to post a loss of $1.38 a shareEarnings Preview - TradingView
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares - Stock Titan
ProMIS Neurosciences Inc (PMN) Stock News Today - TradingKey
Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Promis Neurosciences (PMN) Projected to Post Earnings on Thursday - MarketBeat
Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN - MarketBeat
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):